EP3426250
Meðhöndlun á sjúklingi með CYP3A4 hvarfefnislyfi sem er frábent fyrir samfarandi gjöf með sterkum CYP3A4 hindra
:
EP einkaleyfi í gildi á Íslandi:
16.5.2017:
23.3.2022:
17897227.9
:
3.5.2022:
15.6.2022
:
15.5.2037:
15.5.2026:
31.5.2026
:
TREATING A PATIENT WITH A CYP3A4 SUBSTRATE DRUG CONTRAINDICATED FOR CONCOMITANT ADMINISTRATION WITH A STRONG CYP3A4 INHIBITOR
16.5.2017
23.3.2022
3.5.2022
15.6.2022
15.5.2026
:
Bow River LLC:
2012 Seadrift Drive, Corona Del Mar, California 92625, US
:
SRINIVASAN, Sundar:
Corona del Mar, California 92625, US
:
CHOW, Christina:
Seattle, WA 98112, US
:
Árnason Faktor ehf.:
Guðríðarstíg 2-4, 113, Reykjavík,
:
US2017032924:
16.5.2017
:
A61K 31/502, A61K 31/4545, A61K 31/47, A61K 31/675, A61K 31/506, A61K 31/519, A61K 31/4178, A61K 31/44, A61K 31/05, A61K 31/496, A61K 31/4985, A61P 9/00, A61P 25/24, A61K 31/495, A61P 35/02, A61P 35/04
: 6
: 25.5.2022
: 15.5.2023
: Árnason Faktor ehf.
: 7
: 12.4.2023
: 15.5.2024
: Árnason Faktor ehf.
: 8
: 5.4.2024
: 15.5.2025
: Árnason Faktor ehf.
: 9
: 6.5.2025
: 15.5.2026
: Árnason Faktor ehf.